Acorah Software Products - Accounts Production 16.8.310 false true 31 March 2024 1 April 2023 false 1 April 2024 31 March 2025 31 March 2025 12987888 Mr. I Inkster iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12987888 2024-03-31 12987888 2025-03-31 12987888 2024-04-01 2025-03-31 12987888 frs-core:CurrentFinancialInstruments 2025-03-31 12987888 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-03-31 12987888 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-03-31 12987888 frs-core:ShareCapital 2025-03-31 12987888 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31 12987888 frs-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12987888 frs-bus:FilletedAccounts 2024-04-01 2025-03-31 12987888 frs-bus:SmallEntities 2024-04-01 2025-03-31 12987888 frs-bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 12987888 frs-bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 12987888 frs-bus:Director1 2024-04-01 2025-03-31 12987888 frs-countries:EnglandWales 2024-04-01 2025-03-31 12987888 2023-03-31 12987888 2024-03-31 12987888 2023-04-01 2024-03-31 12987888 frs-core:CurrentFinancialInstruments 2024-03-31 12987888 frs-core:ShareCapital 2024-03-31 12987888 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31
Registered number: 12987888
Deep Pharma Intelligence Ltd
Financial Statements
For The Year Ended 31 March 2025
BBK Partnership
Chartered Accountants & Statutory Auditors
1 Beauchamp Court Victors Way
Barnet
Hertfordshire
EN5 5TZ
Deep Pharma Intelligence Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Deep Pharma Intelligence Ltd
Balance Sheet
As At 31 March 2025
Balance Sheet
Registered number: 12987888

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 294,233 |  | 294,233
|  |  | 294,233 |  | 294,233
CURRENT ASSETS
Debtors | 5 | 4,795 |  | 4,933 |
Cash at bank and in hand |  | 2,392 |  | 151 |
|  | 7,187 |  | 5,084 |
Creditors: Amounts Falling Due Within One Year | 6 | (347,147 ) |  | (318,245 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (339,960 ) |  | (313,161 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (45,727 ) |  | (18,928 )
NET LIABILITIES |  |  | (45,727 ) |  | (18,928 )
CAPITAL AND RESERVES
Called up share capital | 7 |  | 10,000 |  | 10,000
Profit and Loss Account |  |  | (55,727 ) |  | (28,928 )
SHAREHOLDERS' FUNDS |  |  | (45,727) |  | (18,928)

Page 1
Page 2
Deep Pharma Intelligence Ltd
Balance Sheet (continued)
As At 31 March 2025
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr. I Inkster Director
17/03/2026

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Deep Pharma Intelligence Ltd
Notes to the Financial Statements
For The Year Ended 31 March 2025
Notes to the Financial Statements
1. General Information
Deep Pharma Intelligence Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12987888 . The registered office is 63-66 Hatton Garden, 5th Floor, Suite 23, London, EC1N 8LE.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Research and Development
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research is recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised to ... on a straight line basis over their expected useful economic lives, which range from ... to ... years.
If it is not possible to distinguish between the research phase and the development phase of an internal project the expenditure is treated as if it were all incurred in the research phase only.
2.4. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2024: 1)
1 1
Page 3
Page 4
Deep Pharma Intelligence Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2025
4. Intangible Assets

| Development Costs
--- | ---
| £
Cost
As at 1 April 2024 | 326,926
As at 31 March 2025 | 326,926
Amortisation
As at 1 April 2024 | 32,693
As at 31 March 2025 | 32,693
Net Book Value
As at 31 March 2025 | 294,233
As at 1 April 2024 | 294,233

5. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 3,350 |  | 3,418
Other debtors | 1,445 |  | 1,515
| 4,795 |  | 4,933

6. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 12,844 |  | 12,735
Other creditors | 353,039 |  | 324,176
Taxation and social security | (18,736 ) |  | (18,666 )
| 347,147 |  | 318,245

7. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 10,000 |  | 10,000

Page 4